Bildkälla: Stockfoto

Xvivo Perfusion: Q3 Solid growth - Redeye

XVIVO delivers a Q3 with 35% organic (CER) growth which is booth solid and ahead of our expectations. This is achieved despite some headwind in Abdominal Machenery. The other main value driver is disposables and the gross margins continues to improve.

XVIVO delivers a Q3 with 35% organic (CER) growth which is booth solid and ahead of our expectations. This is achieved despite some headwind in Abdominal Machenery. The other main value driver is disposables and the gross margins continues to improve.
Börsvärldens nyhetsbrev
ANNONSER